Hyperuricaemia in gout

Active Ingredient: Lesinurad

Indication for Lesinurad

Population group: only adults (18 years old or older)

Lesinurad, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.

For this indication, competent medicine agencies globally authorize below treatments:

200 mg once daily

Route of admnistration

Oral

Defined daily dose

200 - 200 mg

Dosage regimen

From 200 To 200 mg once every day

Detailed description

The recommended dose of lesinurad is 200 mg once daily in the morning. This is also the maximum dose.

Lesinurad tablets must be co-administered at the same time as the morning dose of a xanthine oxidase inhibitor, i.e. allopurinol or febuxostat. The recommended minimum dose of allopurinol is 300 mg, or 200 mg for patients with moderate renal impairment (creatinine clearance [CrCL] of 30-59 mL/min). If treatment with the xanthine oxidase inhibitor is interrupted, lesinurad dosing must also be interrupted.

Patients should be informed that failure to follow these instructions may increase the risk of renal events.

Patients should be instructed to stay well hydrated (e.g. 2 litres of liquid per day).

The target serum uric acid level is less than 6 mg/dL (360 ยตmol/L). In patients with tophi or persistent symptoms, the target is less than 5 mg/dL (300 ยตmol/L). Testing for the target serum uric acid level may be performed as early as 4 weeks after initiating lesinurad treatment.

Gout flare prophylaxis with colchicine or a nonsteroidal anti-inflammatory drug (NSAID) is recommended for at least 5 months when starting therapy.

Elderly (โ‰ฅ65 years)

No dose adjustment is necessary based on age; however, elderly patients are more likely to have decreased renal function (see dosing recommendations for renal impairment). Experience in very elderly (โ‰ฅ75 years) is limited.

Dosage considerations

Lesinurad should be taken in the morning with food and water.

Active ingredient

Lesinurad

Lesinurad is a selective uric acid reabsorption inhibitor that inhibits uric acid transporter URAT1. URAT1 is responsible for the majority of the reabsorption of filtered uric acid from the renal tubular lumen. By inhibiting URAT1, lesinurad increases uric acid excretion and thereby lowers serum uric acid (sUA). Lesinurad also inhibits OAT4, a uric acid transporter involved in diuretic-induced hyperuricaemia.

Read more about Lesinurad

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.